Identification of Tyrosine Residues in Vascular Endothelial Growth Factor Receptor-2/FLK-1 Involved in Activation of Phosphatidylinositol 3-Kinase and Cell Proliferation

Volkan Dayanir, Rosana Meyer, Kameran Lashkari, Nader Rahimi

Journal of Biological Chemistry · 2001 · 171 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in vasculogenesis and angiogenesis. However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular domain of human CSF-1R/c-fms, fused with the entire transmembrane and cytoplasmic domains of murine VEGFR-2 (Rahimi, N., Dayanir, V., and Lashkari, K. (2000) J. Biol. Chem. 275, 16986–16992). In this study we used VEGFR-2 chimera (herein named CKR) to elucidate the signal transduction relay of VEGFR-2 in porcine aortic endothelial (PAE) cells. Mutation of tyrosines 799 and 1173 individually on CKR resulted in partial loss of CKR's ability to stimulate cell growth. Double mutation of these sites caused total loss of CKR's ability to stimulate cell growth. Interestingly, mutation of these sites had no effect on the ability of CKR to stimulate cell migration. Further analysis revealed that tyrosines 799 and 1173 are docking sites for p85 of phosphatidylinositol 3-kinase (PI3K). Pretreatment of cells with wortmannin, an inhibitor of PI3K, and rapamycin, a potent inhibitor of S6 kinase, abrogated CKR-mediated cell growth. However, expression of a dominant negative form of ras (N17ras) and inhibition of the mitogen-activated protein kinase (MAPK) pathway by PD98059 did not attenuate CKR-stimulated cell growth. Altogether, these results demonstrate that activation of VEGFR-2 results in activation of PI3K and that activation of PI3K/S6kinase pathway, but not Ras/MAPK, is responsible for VEGFR-2-mediated cell growth. Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in vasculogenesis and angiogenesis. However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular domain of human CSF-1R/c-fms, fused with the entire transmembrane and cytoplasmic domains of murine VEGFR-2 (Rahimi, N., Dayanir, V., and Lashkari, K. (2000) J. Biol. Chem. 275, 16986–16992). In this study we used VEGFR-2 chimera (herein named CKR) to elucidate the signal transduction relay of VEGFR-2 in porcine aortic endothelial (PAE) cells. Mutation of tyrosines 799 and 1173 individually on CKR resulted in partial loss of CKR's ability to stimulate cell growth. Double mutation of these sites caused total loss of CKR's ability to stimulate cell growth. Interestingly, mutation of these sites had no effect on the ability of CKR to stimulate cell migration. Further analysis revealed that tyrosines 799 and 1173 are docking sites for p85 of phosphatidylinositol 3-kinase (PI3K). Pretreatment of cells with wortmannin, an inhibitor of PI3K, and rapamycin, a potent inhibitor of S6 kinase, abrogated CKR-mediated cell growth. However, expression of a dominant negative form of ras (N17ras) and inhibition of the mitogen-activated protein kinase (MAPK) pathway by PD98059 did not attenuate CKR-stimulated cell growth. Altogether, these results demonstrate that activation of VEGFR-2 results in activation of PI3K and that activation of PI3K/S6kinase pathway, but not Ras/MAPK, is responsible for VEGFR-2-mediated cell growth. vascular endothelial growth factor receptor phosphatidylinositol 3-kinase phospholipase-Cγ1 vascular endothelial growth factor porcine aortic endothelial cells VEGFR-2 chimera mitogen-activate protein kinase a MAPK inhibitor Dulbecco's modified Eagle's medium adrenal microvascular endothelial cells phosphotyrosine glutathione S-transferase phosphatidylinositol 3-phosphate Vascular endothelial growth factor receptor-1 (VEGFR-11/FLT-1) and VEGFR-2 (FLK-1/KDR) belong to a subfamily of receptor tyrosine kinases implicated in vasculogenesis and angiogenesis. The important contribution of VEGFR-2 in vasculogenesis and angiogenesis was initially underscored by the observation that homozygous knockout mice lacking VEGFR-2 exhibited severe deficiency in vessel formation (1Shalaby F. Rossant J. Yamaguchi T.P. Gertsentein M. Fu Wu X. Breitman M.L. Schuh A.C. Nature. 1995; 376: 62-66Crossref PubMed Scopus (3370) Google Scholar). Furthermore, introduction of either a neutralizing antibody against VEGF or the dominant negative form of VEGFR-2 was able to block angiogenesis (2Millauer B. Shawver L.K. Plate K.H. Risau W. Ullrich A. Nature. 1994; 367: 576-579Crossref PubMed Scopus (1162) Google Scholar, 3Kim K.J. Li B. Winer J. Armanini M. Gillett N. Phillips H.S. Ferrara N. Nature. 1993; 362: 841-844Crossref PubMed Scopus (3362) Google Scholar). On the other hand, VEGFR-1 activation alone appears to play a less significant role in these cellular processes (4Fong G.H. Zhang L. Bryce D.M. Peng J. Development. 1999; 126: 3015-3025Crossref PubMed Google Scholar, 5Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar, 6Hiratsuka S. Minowa O. Kuno J. Noda T. Shibuya M. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 9349-9354Crossref PubMed Scopus (896) Google Scholar). The mechanism by which VEGFR-2 activation evokes angiogenesis is not well understood. It is presumed that these events are initiated by binding of VEGF to VEGFR-2 leading to tyrosine phosphorylation of the dimerized VEGFR-2 and subsequent phosphorylation of SH2-containing intracellular signaling proteins, including phospholipase C-γ1 (PLCγ1), Src family tyrosine kinases, and phosphatidylinositol 3-kinase (PI3K), adaptor molecules, SHC, NCK, and Ras GTPase-activating protein (7Waltenberger J. Calaesson-Welsh L. Siegbahn A. Shibuya M. Heldin C.-H. J. Biol. Chem. 1994; 269: 26988-26995Abstract Full Text PDF PubMed Google Scholar, 8Takahashi T. Shibuya M. Oncogene. 1997; 4: 2079-2089Crossref Scopus (273) Google Scholar, 9Igarashi K. Isohara T. Kato T. Shigeta K. Yamano T. Uno I. Biochem. Biophys. Res. Commun. 1998; 246: 95-99Crossref PubMed Scopus (51) Google Scholar, 10Guo D. Jia Q. Song H.Y. Warren R.S. Donner D.B. J. Biol. Chem. 1995; 270: 6729-6733Abstract Full Text Full Text PDF PubMed Scopus (416) Google Scholar). The contributions of individual signaling molecules to various aspects of angiogenesis and the tyrosine sites on VEGFR-2 that potentially mediate their recruitment and activation have not been fully investigated. Moreover, the data presented in the literature is often inconsistent. Waltenbergeret al. (1994), Abedi and Zachary (1997), and Takahashiet al. (1997) have suggested that stimulation of endothelial cells with VEGF results in no PI3K activation (7Waltenberger J. Calaesson-Welsh L. Siegbahn A. Shibuya M. Heldin C.-H. J. Biol. Chem. 1994; 269: 26988-26995Abstract Full Text PDF PubMed Google Scholar, 8Takahashi T. Shibuya M. Oncogene. 1997; 4: 2079-2089Crossref Scopus (273) Google Scholar, 11Abedi H. Zachary I. J. Biol. Chem. 1997; 272: 15442-15451Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar), whereas others have shown that VEGFR-2 activation does indeed result in PI3K stimulation, which may stimulate endothelial cell growth and survival (12Thakker G.D. Hajjar D.P. Muller W.A. Rosengart T.K. J. Biol. Chem. 1999; 274: 10002-10007Abstract Full Text Full Text PDF PubMed Scopus (219) Google Scholar, 13Gerber H.P. McMurtrey A. Kowalski J. Yan M. Keyt B.A. Dixit V. Ferrara N. J. Biol. Chem. 1998; 273: 30336-30343Abstract Full Text Full Text PDF PubMed Scopus (1746) Google Scholar). The reason for the apparent inconsistency in the activation and association of signaling molecules with VEGFR-2 is not known. It may be due to the complexity of VEGFR-2-mediated signal transduction relay in endothelial cells such as expression of VEGFR-1 and neuropilin-1 and -2, which may modify or antagonize VEGFR-2-mediated signal transduction and its final biological responses (5Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar, 14Soker S. Takashima S. Miao H.Q. Neufeld G. Klagsbrun M. Cell. 1998; 92: 735-745Abstract Full Text Full Text PDF PubMed Scopus (2088) Google Scholar, 15Kendall R.L. Wang G. Thomas K.A. Biochem. Biophys. Res. Commun. 1996; 226: 324-328Crossref PubMed Scopus (628) Google Scholar). To circumvent these issues, we have recently constructed a chimeric receptor containing the extracellular domain of human CSF-1R/c-fms, fused with the transmembrane and the cytoplasmic domains of murine VEGFR-2. (5Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). This model permitted us to dissect the functions of VEGFR-2 in endothelial cells by selectively stimulating the receptor with CSF-1. In this study we used this chimeric receptor to elucidate the signal transduction relay induced by VEGFR-2 in PAE cells. We show that mutation of tyrosine sites 799 and 1173 individually on CKR result in partial loss of CKR's ability to stimulate cell growth, whereas double mutation of these tyrosine sites result in complete loss of CKR ability to stimulate endothelial cell growth. Mutation of these sites, however, had no effect on CKR's ability to stimulate cell migration. Further analysis showed that tyrosines 799 and 1173 are binding sites for p85 of PI3K and that activation of PI3K is responsible for CKR-mediated endothelial cell growth. Mouse anti-phosphotyrosine (PY-20), anti-PLCγ, anti-mouse, and anti-rabbit secondary antibodies were purchased from Transduction Laboratories (Lexington, KY). Rabbit anti-MAPK, anti-phospho-MAPK, anti-phospho-S6 kinase and anti-phospho-AKT antibodies were purchased from New England BioLabs (Boston, MA). Pan anti-Ras antibody was purchased from Oncogene Science (Boston, MA). Rabbit anti-phospho-PLCγ antibody was purchased fromBIOSOURCE (Camarillo, CA). Rabbit anti-VEGFR-2 antibody was made to amino acids corresponding to kinase insert of VEGFR-2. Wortmannin and rapamycin were purchased from Sigma Chemical Co. (St. Louis, MO). PD98059 was purchased from Calbiochem (San Diego, CA). GST-SH2 fusion proteins of p85 were purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Porcine aortic endothelial (PAE) cells expressing chimeric CKR and three mutants, CKR/F799, CKR/F1173, and CKR/F2, were established by a retroviral system as described previously (5Rahimi N. Dayanir V. Lashkari K. J. Biol. Chem. 2000; 275: 16986-16992Abstract Full Text Full Text PDF PubMed Scopus (197) Google Scholar). Briefly, cDNA encoding for CKR, CKR/F799, CKR/F1173, and CKR/F2 were cloned into retroviral vector, pLNCX2and transfected into 293GPG cells. Viral supernatants were collected for 7 days, concentrated by centrifugation, and used as previously described (16Ory D.S. Neugeboren B.A. Mulligan R.C. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 11400-11406Crossref PubMed Scopus (801) Google Scholar). The VEGFR-2 chimera (CKR) was used as a template to construct the mutations. CKR was subcloned into pGEMT cloning vector, and site-directed mutagenesis was carried out by using the Stratagene site-directed mutagenesis kit. Site-directed mutagenesis primers for replacement of tyrosines 799 and 1173 to phenylalanine were CTGAAGACAGGCTTCTTGTCTATTGTC and CCGGATTTCGTTCGAAAAGG, respectively. The resultant mutations were verified by sequencing and were subsequently cloned into pLNCX2 vector by NotI and SalI sites. PAE cells expressing CKR and CKR mutants were grown in semi-confluent culture condition in DMEM containing 10% fetal bovine serum supplemented with glutamate, penicillin, and streptomycin, and serum-starved overnight in DMEM. Cells were left either resting or stimulated with 20 ng/ml CSF-1 for 10 min, at 37 °C. Cells were washed twice with H/S and in 10% and 20 were by using were to protein and washed three with of were on a and the proteins were to the were for in containing 10 10 bovine serum were in antibodies in for was washed three in with and with were by in a containing and at for min, washed in and with antibody of PI3K was in using anti-phosphotyrosine antibody as previously described N. B. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar). Briefly, were washed twice with containing with and and twice with 10 and were in a final of 10 of containing a of phosphatidylinositol at a final of and 10 of of at the was by 20 of and were by of The in the were and with was in The was and The was as described N. W. B. J. Biol. Chem. 1998; 273: Full Text Full Text PDF PubMed Scopus Google Scholar). Briefly, cells were at in containing DMEM supplemented with 10% fetal bovine and at 37 for Cells were washed with and serum-starved with DMEM containing bovine serum for Cells were various of CSF-1 either or with various of PD98059 or as in the the of cells were with and for were collected from was three and the results were The data are presented as of PAE cells expressing CKR and CKR mutants was using the CSF-1 was in DMEM to a of ng/ml and in the of the with were in of containing of for were washed twice with and the and of the cells were and in DMEM to a of and of this was into were at 37 for the were and and with washed with and on The cell was with a cells that had the were at were used for a of in The was three and the results were The data are presented as of cells To elucidate the signal transduction relay induced by VEGFR-2 in endothelial we tyrosines 799 and 1173 on the chimeric VEGFR-2 either individually or by with mutants were CKR/F799, CKR/F1173, and 799 and 1173 are in the and of CKR, CKR and tyrosine were in PAE cells using a retroviral To were on on PAE cells expressing either vector CKR, CKR/F1173, and CKR/F2 were and of protein of total cell were to analysis by using anti-VEGFR-2 that the are at of CKR in PAE cells is to the expression of VEGFR-2 in adrenal microvascular endothelial cells N. A. Biol. Cell. 1999; PubMed Scopus Google Scholar). To that the cells were indeed are for we PAE cells expressing CKR and tyrosine to analysis by using anti-VEGFR-2 The result showed that the cells CKR not we the tyrosine phosphorylation of in to CSF-1 PAE cells expressing CKR and various were stimulated with CSF-1 for 10 min, and with anti-VEGFR-2 The proteins were to anti-phosphotyrosine that CKR and as well as were in a that were and that replacement of tyrosines 799 and 1173 to phenylalanine in CKR did not from to CSF-1 To tyrosines 799 and 1173 are for CKR-mediated biological responses in the endothelial we PAE cells expressing CKR and to and stimulation of PAE cells expressing CKR with CSF-1 induced their growth in a The CSF-1 in cells expressing and was in PAE cells expressing CSF-1 in cells expressing CKR/F2 was and of cells with of CSF-1 did not their growth the ability of tyrosine to stimulate cell growth was by other by using or of cells by using results were by using these not results that tyrosines 799 and 1173 are for CKR-mediated cell growth. CSF-1 stimulation of cells expressing caused with their This effect of CSF-1 was at of that tyrosines 799 and 1173 may by either cell or by other Dayanir, D. K. Lashkari, and N. VEGFR-2 is with endothelial cell (7Waltenberger J. Calaesson-Welsh L. Siegbahn A. Shibuya M. Heldin C.-H. J. Biol. Chem. 1994; 269: 26988-26995Abstract Full Text PDF PubMed Google Scholar), we tyrosines 799 and 1173 on CKR was for CKR-mediated cell migration. To this PAE cells expressing CKR and were to The result showed that CSF-1 stimulation of PAE cells expressing CKR and resulted in a significant stimulation of PAE cells expressing CKR/F799, CKR/F1173, and CKR/F2 with CSF-1 resulted in tyrosines 799 and 1173 on VEGFR-2 to be in recruitment and activation signaling molecules with cell are with cell in PAE cells. To PI3K is by CKR and tyrosines 799 and 1173 to its recruitment by we PAE cells expressing CKR and to an in PI3K of PAE cells expressing CKR with CSF-1 resulted in activation of PI3K, as by However, by and was by CKR/F2 was to stimulate It is that the CKR-mediated PI3K activation is established by p85 of PI3K and To this serum-starved PAE cells expressing CKR, CKR/F799, CKR/F1173, and CKR/F2 were stimulated with and cell were with anti-VEGFR-2 were and to using shown in p85 was from anti-VEGFR-2 of cell from cells expressing CKR but not from of CKR/F799, CKR/F1173, and of the showed of p85 in and but not in CKR/F2 not that binding of p85 to CKR is not and tyrosines 799 and 1173 may be as binding sites for The to p85 in cells expressing CKR/F799, CKR/F1173, and CKR/F2 was not due to the of CKR CKR protein was in been that the domains of p85 are for formation p85 and other tyrosine proteins M. G. T. T. 1993; Full Text PDF PubMed Scopus Google Scholar). To the ability of the p85 domains to CKR, cell from PAE cells expressing CKR were for their to a and The proteins were and CKR was by with an anti-VEGFR-2 In a of and of p85 with CKR but not in cells. In of the protein with alone did result in binding to CKR data show that p85 to CKR in and in and that tyrosines 799 and 1173 play a role in this p85 binding domains of the domain exhibited binding to CKR that of the in a To the role of the PI3K pathway in this system we phosphorylation of a of this serum-starved cells were stimulated with CSF-1 and total cell were to an The result showed that stimulation of cells expressing CKR results in activation of in a these results that stimulation of VEGFR-2 results in PI3K activation and that tyrosines 799 and 1173 of VEGFR-2 are responsible for its association with p85 and activation of of To activation of signaling molecules by we this serum-starved cells were stimulated with CSF-1 and cell were either with an antibody and to anti-phosphotyrosine or total cell were to an anti-phospho-PLCγ The results showed that CKR and the were able to stimulate tyrosine phosphorylation of and no in tyrosine phosphorylation of was CKR/F799, CKR/F1173, or CKR/F2 in and results that tyrosines 799 and 1173 are not for activation of and other tyrosine sites on VEGFR-2 may as docking sites for this appears that mutations of tyrosines 799 and 1173 on VEGFR-2 not the ability of this receptor to that these sites as binding sites for p85 of To the of PI3K in CKR-mediated cell growth, we used an by using wortmannin, a inhibitor of PI3K H. S. K. N. J. Biol. Chem. 1993; Full Text PDF PubMed Google Scholar). To this PAE cells expressing CKR, were with of wortmannin, stimulated with CSF-1 and cells to a that of cells with cell growth in a This result with the site-directed mutagenesis data that PI3K activation plays a role in endothelial cell To and the of in this system in endothelial cell we the role of S6 kinase, a of this serum-starved PAE cells expressing CKR and tyrosine were stimulated with and total cell were to an anti-phospho-S6 kinase The results showed that CKR is able to stimulate phosphorylation of S6 kinase in a and were able to stimulate S6 kinase whereas CKR/F2 to stimulate S6 kinase phosphorylation in the condition To S6 kinase is for CKR-mediated PAE cell serum-starved cells were with rapamycin, an inhibitor of and as a of S6 kinase A. Thomas G. Nature. 1993; PubMed Scopus Google Scholar). The result showed that rapamycin CKR-stimulated PAE cell growth that the kinase pathway is responsible for VEGFR-2-mediated endothelial cell growth. of PAE cells with rapamycin CSF-1 stimulation growth of PAE that S6 kinase is for growth of PAE cells. This effect of rapamycin does not to be due to of rapamycin, at ng/ml phosphorylation of S6 kinase by not is for of rapamycin may effect activation of signaling molecules other S6 kinase that be in growth of PAE cells. we the of these to stimulate MAPK this PAE cells expressing CKR and were stimulated with and and of proteins of total cell were to analysis using The result that are able to stimulate MAPK as with CKR In phosphorylation of MAPK by was not at to of stimulation with CSF-1 not To MAPK activation plays a role in CKR-mediated cell growth, we PAE cells expressing CKR to in which cells were with a potent and inhibitor of kinase inhibitor A. J. Biol. Chem. 1995; 270: Full Text Full Text PDF PubMed Scopus Google Scholar). PD98059 of PAE cells expressing CKR did not CKR-mediated cell these data CKR activation results in MAPK its may not be for CKR-mediated cell growth in PAE cells. To that PD98059 at the used in indeed is MAPK we MAPK of cells with PD98059 MAPK MAPK activation is by we its role in this this we in cells by a system and the cells to The result showed that expression of the dominant negative form of ras (N17ras) had a effect on the cell growth 7 expression of in cells. these results that activation of the pathway is not for VEGFR-2-mediated PAE cell study that mutation of tyrosines 799 and 1173 on VEGFR-2 binding of of PI3K to CKR CKR's ability to and mutation of 799 and 1173 on CKR PI3K activation and cell double mutation of tyrosines 799 and 1173 CKR's ability to stimulate PI3K activation and endothelial cell growth but not cell migration. results that signaling are by VEGFR-2 and are responsible for the of endothelial cell growth and for angiogenesis. with of cells with wortmannin, a potent inhibitor of PI3K, CKR's ability to stimulate cell growth. Activation of PI3K results in which protein kinase W. J. L.K. A.C. A. Biol. 1998; Full Text Full Text PDF PubMed Google Scholar), D. T. F. 1997; PubMed Scopus Google Scholar), and stimulation of S6 kinase A. K.A. A. J. Cell. Biol. 1999; PubMed Google Scholar). results show that rapamycin, a potent inhibitor of the S6 kinase pathway A. Thomas G. Nature. 1993; PubMed Scopus Google Scholar), CKR-mediated cell growth, that the kinase pathway is responsible for CKR-mediated cell growth. Interestingly, appears that activation of the and is not in growth of PAE cells. activation of these by CKR that these molecules are to in the other cellular processes such as cell and cell of have the role in signal The suggested that activation is in cells T. Shibuya M. Oncogene. 1997; 4: 2079-2089Crossref Scopus (273) Google Scholar, 9Igarashi K. Isohara T. Kato T. Shigeta K. Yamano T. Uno I. Biochem. Biophys. Res. Commun. 1998; 246: 95-99Crossref PubMed Scopus (51) Google Scholar, Biochem. Biophys. Res. Commun. 1997; PubMed Scopus Google Scholar). study showed that tyrosine on the human VEGFR-2 is a binding for Wang D. Warren R.S. Donner D.B. J. Biol. Chem. 2000; 275: Full Text Full Text PDF PubMed Scopus Google Scholar). In with this results demonstrate that tyrosines 799 and 1173 of VEGFR-2 are not for activation and tyrosine is the binding for In results demonstrate is by its activation is not for endothelial cell growth. Activation of been shown to stimulate cell growth and in a of cellular however, its role in VEGFR-2-mediated signal transduction and endothelial cell is been suggested that inhibition of by endothelial cell growth T. H. Shibuya M. Oncogene. 1999; PubMed Scopus Google Scholar). cells VEGFR-1 and is to the contributions of receptor to the that tyrosines 799 and 1173 are p85 docking sites for p85 of PI3K, may binding sites for tyrosine 799 and 1173 of VEGFR-2 not to p85 binding sites Cell. 1995; Full Text PDF PubMed Scopus Google Scholar, Biophys. 1996; Google Scholar). is that domains of p85 to receptor tyrosine kinases this other binding sites for p85 of PI3K have been p85 binding to the growth factor receptor including and is by the J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar, A. F. S. A. G. Cell. 1994; Full Text PDF PubMed Scopus (896) Google Scholar). been that amino acids on VEGFR-1 is a binding for p85 J. Biol. Chem. 1995; 270: Full Text Full Text PDF PubMed Scopus Google Scholar). for the of PI3K in VEGFR-2-mediated signal transduction and angiogenesis. The that PI3K may be be from the activation of PI3K by VEGFR-2 suggested that PI3K is not by VEGFR-2 stimulation (7Waltenberger J. Calaesson-Welsh L. Siegbahn A. Shibuya M. Heldin C.-H. J. Biol. Chem. 1994; 269: 26988-26995Abstract Full Text PDF PubMed Google Scholar, 8Takahashi T. Shibuya M. Oncogene. 1997; 4: 2079-2089Crossref Scopus (273) Google Scholar, 11Abedi H. Zachary I. J. Biol. Chem. 1997; 272: 15442-15451Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar). However, subsequent suggested that VEGF stimulation of endothelial cells results in activation of PI3K and its activation may endothelial cell survival (12Thakker G.D. Hajjar D.P. Muller W.A. Rosengart T.K. J. Biol. Chem. 1999; 274: 10002-10007Abstract Full Text Full Text PDF PubMed Scopus (219) Google Scholar, 13Gerber H.P. McMurtrey A. Kowalski J. Yan M. Keyt B.A. Dixit V. Ferrara N. J. Biol. Chem. 1998; 273: 30336-30343Abstract Full Text Full Text PDF PubMed Scopus (1746) Google Scholar). Furthermore, recently been shown that PI3K angiogenesis in the by stimulating VEGF expression M. Proc. Natl. Acad. Sci. U. S. A. 2000; PubMed Scopus Google Scholar). angiogenesis VEGF endothelial cell growth, and in a study that activation of VEGFR-2 in endothelial cells a of signaling molecules, including PI3K, and Altogether, this that angiogenesis stimulation of the kinase pathway by VEGFR-2 may endothelial cell growth and endothelial cell survival leading to formation of have suggested that activation of the kinase pathway is for serum and growth endothelial cell growth F. J. J. Biol. Chem. 1999; 274: Full Text Full Text PDF PubMed Scopus Google Scholar, S. Thomas G. L. J. Biol. Chem. 1997; 272: Full Text Full Text PDF PubMed Scopus Google Scholar), that activation of PI3K by a of in the endothelial cells as a to cell of angiogenesis is the critical in the of and in W. Nature. 1997; PubMed Scopus Google Scholar, J. Cell. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar). The results presented in this tyrosine of VEGFR-2 responsible for and activation of PI3K and its role as a of endothelial cell growth. are important for the of signaling molecules and the aspects of angiogenesis. Further the contributions of other signaling molecules to cellular processes angiogenesis. We for the

References

36